Aliases & Classifications for Rosacea

MalaCards integrated aliases for Rosacea:

Name: Rosacea 12 43 44 15 63 73
Acne, Erythematosa 12
Acne Roscea 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8881
ICD10 33 L71 L71.9
ICD9CM 35 695.3
MeSH 44 D012393
NCIt 50 C97136
UMLS 73 C0035854

Summaries for Rosacea

MedlinePlus : 43 Rosacea is a long-term disease that affects your skin and sometimes your eyes. It causes redness and pimples. Rosacea is most common in women and people with fair skin. It most often affects middle-aged and older adults. In most cases, rosacea only affects the face. Symptoms can include Frequent redness of the face, or flushing Small, red lines under the skin Acne A swollen nose Thick skin, usually on the forehead, chin, and cheeks Red, dry, itchy eyes and sometimes vision problems No one knows what causes rosacea. You may be more likely to have it if you blush a lot or if rosacea runs in your family. Rosacea is not dangerous. There is no cure, but treatments can help. They include medicines and sometimes surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Rosacea, also known as acne, erythematosa, is related to psoriasis and chlamydia, and has symptoms including exanthema and pruritus. An important gene associated with Rosacea is CAMP (Cathelicidin Antimicrobial Peptide), and among its related pathways/superpathways are Kaposi's sarcoma-associated herpesvirus infection and IL-17 Family Signaling Pathways. The drugs Ivermectin and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are behavior/neurological and cardiovascular system

PubMed Health : 63 About rosacea: Red patches of skin on your face, and tiny visible blood vessels and spots – these can be quite common symptoms. They may be caused by rosacea, a common facial skin inflammation.Skin diseases can be difficult to cope with, and they often affect people’s self-confidence and wellbeing. But if you have rosacea, there is a lot you can do on your own.

Wikipedia : 76 Rosacea is a long-term skin condition that typically affects the face. It results in redness, pimples,... more...

Related Diseases for Rosacea

Diseases related to Rosacea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 250)
# Related Disease Score Top Affiliating Genes
1 psoriasis 29.3 CAMP IL6 TNF VDR
2 chlamydia 29.2 IL6 TLR2 TNF
3 pneumonia 29.1 IL6 TLR2 TNF
4 dermatitis, atopic 28.8 CAMP TLR2 TNF TRPV1
5 gastrointestinal system disease 28.3 IL6 TNF TRPV1
6 rheumatoid arthritis 27.8 IL6 MMP9 TLR2 TNF VEGFA
7 inflammatory bowel disease 27.5 IL6 TLR2 TNF TRPV1 VDR
8 granulomatous rosacea 12.5
9 rosacea conjunctivitis 12.0
10 adult dermatomyositis 10.6 TNF VDR
11 angiokeratoma circumscriptum 10.6 MMP9 VEGFA
12 trench fever 10.6 TLR2 TNF
13 autoimmune inner ear disease 10.6 MMP9 TNF
14 adamantinous craniopharyngioma 10.6 MMP9 VEGFA
15 haemophilus influenzae 10.5 TLR2 TNF
16 microcystic meningioma 10.5 MMP9 VEGFA
17 adenomyosis 10.5 MMP9 VEGFA
18 scleritis 10.5 MMP9 TNF
19 penicilliosis 10.5 TLR2 TNF
20 nontuberculous mycobacterial lung disease 10.5 TLR2 TNF
21 amaurosis fugax 10.5 MMP8 MMP9
22 mycobacterium abscessus 10.5 TLR2 TNF
23 radiation proctitis 10.4 TNF VEGFA
24 odontogenic myxoma 10.4 MMP9 VEGFA
25 primary systemic mycosis 10.4 TLR2 TNF
26 diverticulitis 10.4 MMP9 TNF
27 neovascular glaucoma 10.4 IER3IP1 VEGFA
28 soft tissue sarcoma 10.4 TNF VEGFA
29 anterior uveitis 10.4 IL6 TLR2
30 cellulitis 10.3 CAMP TNF
31 diabetic foot ulcers 10.3 IL6 MMP9
32 alveolar echinococcosis 10.3 TLR2 TNF
33 acute transverse myelitis 10.3 IL6 MMP9
34 melancholia 10.3 IER3IP1 TNF
35 sebaceous gland disease 10.3 IER3IP1 TLR2
36 irritant dermatitis 10.3 IER3IP1 TNF
37 multidrug-resistant tuberculosis 10.3 TNF VDR
38 dermatitis 10.3
39 lepromatous leprosy 10.3 TLR2 TNF VDR
40 scorpion envenomation 10.3 IL6 TNF
41 spinal disease 10.3 IL6 VEGFA
42 leukomalacia 10.3 IL6 TNF
43 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL6 TNF
44 keratitis, hereditary 10.2 MMP9 TLR2 VEGFA
45 streptococcal toxic-shock syndrome 10.2 IL6 TNF
46 null-cell leukemia 10.2 IL6 TNF
47 pulmonary tuberculosis 10.2 TLR2 TNF VDR
48 retinitis pigmentosa 55 10.2 IL6 TNF
49 mycobacterium tuberculosis 1 10.2 TLR2 TNF VDR
50 anca-associated vasculitis 10.2 IL6 TNF

Graphical network of the top 20 diseases related to Rosacea:



Diseases related to Rosacea

Symptoms & Phenotypes for Rosacea

UMLS symptoms related to Rosacea:


exanthema, pruritus

MGI Mouse Phenotypes related to Rosacea:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 VEGFA TRPV1 VDR TNF PTGDR IL6
2 cardiovascular system MP:0005385 10.11 TRPV1 VDR TNF VEGFA TLR2 MMP9
3 cellular MP:0005384 10.1 TNF VEGFA TRPV1 VDR IL6 TLR2
4 immune system MP:0005387 10.1 TRPV1 VDR VEGFA TLR2 MMP8 MMP9
5 homeostasis/metabolism MP:0005376 10.09 TRPV1 VDR TNF VEGFA MMP8 TLR2
6 hematopoietic system MP:0005397 10.06 VEGFA VDR TNF PTGDR IL6 TLR2
7 integument MP:0010771 9.97 TRPV1 VDR TNF VEGFA TLR2 MMP9
8 digestive/alimentary MP:0005381 9.95 VEGFA VDR TNF IL6 TLR2 MMP9
9 muscle MP:0005369 9.87 VDR TNF VEGFA TLR2 MMP9 PTGDR
10 neoplasm MP:0002006 9.8 TRPV1 VEGFA TLR2 MMP8 MMP9 TNF
11 nervous system MP:0003631 9.76 VEGFA TRPV1 VDR TNF PTGDR IL6
12 renal/urinary system MP:0005367 9.43 TRPV1 VDR VEGFA TLR2 MMP9 IL6
13 respiratory system MP:0005388 9.1 VEGFA TNF IL6 TLR2 MMP9 PTGDR

Drugs & Therapeutics for Rosacea

PubMedHealth treatment related to Rosacea: 63

There are a lot of creams, lotions and gels recommended for the treatment of rosacea. Creams and gels with either azelaic acid or the antibiotic metronidazole in them are used most commonly. Antibiotics can also be taken as tablets, but then the entire body is affected.

Drugs for Rosacea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 70288-86-7 6474909
2
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 564-25-0 54671203
3
Aminolevulinic acid Approved Phase 4,Not Applicable 106-60-5 137
4
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
5
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
6
Phenylephrine Approved Phase 4,Phase 3 59-42-7 6041
7
Azelaic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 123-99-9 2266
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1 443-48-1 4173
10
Oxymetazoline Approved, Investigational Phase 4,Phase 3 1491-59-4 4636
11
Sulfacetamide Approved Phase 4 144-80-9 5320
12
Timolol Approved Phase 4,Phase 1 26839-75-8 33624 5478
13 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
17 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1 70359-46-5
20 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1
22 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1
23 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1
24 Mydriatics Phase 4,Phase 3
25 Nasal Decongestants Phase 4,Phase 3,Phase 1,Phase 2
26 Cyclosporins Phase 4
27 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Vasoconstrictor Agents Phase 4,Phase 3,Phase 1,Phase 2
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Photosensitizing Agents Phase 4,Not Applicable
31 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 4,Phase 2
33 Antifungal Agents Phase 4
34 Protective Agents Phase 4,Phase 3
35 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
37 Antimalarials Phase 4,Phase 3,Phase 2,Not Applicable
38 Antirheumatic Agents Phase 4,Phase 2,Phase 1
39 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
40 Calcineurin Inhibitors Phase 4,Phase 2
41 Adrenergic Antagonists Phase 4,Phase 1
42 Adrenergic beta-Antagonists Phase 4,Phase 1
43 Anti-Arrhythmia Agents Phase 4,Phase 1
44
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
45
Ezetimibe Approved Phase 3 163222-33-1 150311
46
Minocycline Approved, Investigational Phase 3,Phase 2,Phase 1 10118-90-8 5281021
47
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
48
Clindamycin Approved, Vet_approved Phase 2, Phase 3 18323-44-9 29029
49
Tretinoin Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 302-79-4 5538 444795
50 tannic acid Approved, Nutraceutical Phase 3

Interventional clinical trials:

(show top 50) (show all 155)
# Name Status NCT ID Phase Drugs
1 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Completed NCT01872715 Phase 4 Oracea
2 Internet Surveys and Their Impact on Adherence for Rosacea Completed NCT03048058 Phase 4 brimonidine topical gel 0.33% & survey;brimonidine topical gel 0.33% & SOC
3 MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. Completed NCT02616250 Phase 4 Brimonidine 0.33% gel (Br);Ivermectin 1% cream (IVM)
4 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed NCT01308619 Phase 4 Doxycycline
5 Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea Completed NCT00855595 Phase 4 Azelaic acid (Finacea, BAY39-6251);Metronidazole (Metrogel);Doxycycline (Oracea)
6 Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study Completed NCT02147691 Phase 4 Azelaic acid 15%;Brimonidine 0.33%
7 Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea Completed NCT03380390 Phase 4 Oxymetazoline HCL 1.0% Cream
8 Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens Completed NCT00495313 Phase 4 doxycycline;doxycycline
9 ORCA - Oracea® for Rosacea: A Community-based Assessment Completed NCT00892281 Phase 4 doxycycline (Oracea®) 40 mg modified release as monotherapy;doxycycline (Oracea®) 40 mg modified release as add-on therapy
10 Efficacy of Topical Cyclosporin for Ocular Rosacea Completed NCT00348335 Phase 4 Cyclosporine 0.05%;Ocular lubricant
11 A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily Completed NCT00417937 Phase 4 azelaic acid 15% gel;azelaic acid 15% gel
12 Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo Completed NCT01426269 Phase 4 Doxycycline;Metronidazole;Placebo
13 Mirvaso in Use Study Completed NCT02249065 Phase 4 Brimonidine
14 Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application Completed NCT00436527 Phase 4 Metronidazole gel 1%
15 Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias Completed NCT02761174 Phase 4 Brimonidine
16 Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea Recruiting NCT03418610 Phase 4 Azelaic Acid foam 15%
17 Photodynamic Therapy for Papulopustular Rosacea Recruiting NCT02075671 Phase 4 Aminolevulinic acid topical solution 20%
18 Oracea Soolantra Association in Patients With Severe Rosacea Active, not recruiting NCT03075891 Phase 4 Ivermectin 1% cream;Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
19 Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea Not yet recruiting NCT03053700 Phase 4 Bromonide 0.33% gel
20 Topical Timolol for the Treatment of Benign Vascular Periocular Lesions Withdrawn NCT01250457 Phase 4 topical Timolol
21 Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis Unknown status NCT02036229 Phase 3 ivermectin cream 0.5%
22 Azelaic Acid on Demodex Counts in Rosacea Completed NCT03035955 Phase 2, Phase 3 Azelaic acid
23 Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed NCT01318733 Phase 3 CD07805/47 gel 0.5%
24 Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea Completed NCT01555463 Phase 3 Azelaic acid foam, 15% (BAY39-6251);Vehicle foam
25 Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT02289352 Phase 3 Brimonidine;placebo
26 A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea Completed NCT02393937 Phase 3 Reference: Metronidazole Gel 1%;Test: Metronidazole Gel 1%;Placebo Gel
27 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed NCT01355458 Phase 3 CD07805/47 gel;Placebo
28 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed NCT01355471 Phase 3 CD07805/47 Gel;Placebo
29 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea Completed NCT02120924 Phase 3 Azelaic acid
30 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Patients With Rosacea Completed NCT03287791 Phase 3 Azelaic acid (Finacea®) Foam;Generic Azelaic Acid Foam;Vehicle Foam
31 An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea Completed NCT03352323 Phase 3 Oxymetazoline
32 Phase 3 Papulopustular Rosacea Study Completed NCT01494467 Phase 3 CD5024;Azelaic acid 15% Gel
33 Phase 3 Papulopustular Rosacea Study Completed NCT01493687 Phase 3 CD5024;Azelaic acid 15% Gel
34 Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea Completed NCT02132117 Phase 3 Oxymetazoline HCL Cream 1.0%;Vehicle to Oxymetazoline HCL Cream
35 Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea Completed NCT00041977 Phase 3 doxycycline hyclate 20 mg twice daily
36 A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea Completed NCT02095158 Phase 3 Oxymetazoline HCL Cream 1.0%
37 Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea Completed NCT00823901 Phase 2, Phase 3 Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel;Placebo gel
38 Isotretinoin in Papular-Pustular Rosacea Completed NCT00882531 Phase 3 isotretinoin;placebo
39 CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study Completed NCT01493947 Phase 3 Ivermectin 1% cream;Metronidazole 0.75% cream
40 Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea Completed NCT01016782 Phase 3 0444
41 Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Completed NCT01659853 Phase 3 CD07805/47 gel 0.5%/CD07805/47 Vehicle;azelaic acid gel 15%
42 A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea Completed NCT00126399 Phase 3 doxycycline
43 Clinical Endpoint Study of Ivermectin 1% Cream Completed NCT02840461 Phase 3 Ivermectin Cream, 1%;Placebo/Vehicle cream
44 Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea Completed NCT02131636 Phase 3 AGN-199201;Vehicle to AGN-199201
45 Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face Completed NCT02800148 Phase 3 Azelaic acid foam;Azelaic acid foam;Azelaic acid foam - Placebo
46 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea Completed NCT02795117 Phase 3 Ivermectin;Ivermectin (reference);Placebo
47 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed NCT01789775 Phase 3 Drug: CD07805/47 gel;CD07805/47 gel Placebo
48 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea Completed NCT02385240 Phase 3 Brimonidine Topical Gel, 0.33 percent (Perrigo);Brimonidine Topical Gel, 0.33 percent (Reference);Placebo gel
49 Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel Completed NCT02576847 Phase 3 Omiganan
50 Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Completed NCT02576860 Phase 3 CLS001 (Omiganan);Vehicle

Search NIH Clinical Center for Rosacea

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: rosacea

Genetic Tests for Rosacea

Anatomical Context for Rosacea

MalaCards organs/tissues related to Rosacea:

41
Skin, Eye, Testes, Heart, Small Intestine, B Cells, Endothelial

Publications for Rosacea

Articles related to Rosacea:

(show top 50) (show all 737)
# Title Authors Year
1
Successful treatment of erythematotelangiectatic rosacea with intense pulsed light: Report of 13 cases. ( 29952023 )
2018
2
Efficacy and Safety of Oxymetazoline Cream 1.0% for Treatment of Persistent Facial Erythema Associated With Rosacea: Findings From the 52-Week Open Label REVEAL Trial. ( 29409914 )
2018
3
In Vitro Safety Pharmacology Profiling of Topical I+-Adrenergic Agonist Treatments for Erythema of Rosacea. ( 29374829 )
2018
4
Rosacea-like demodicosis (but not primary demodicosis) and papulo pustular rosacea may beA two phenotypes of the same disease-a microbioma,therapeutic and diagnostic tools perspective. ( 29959784 )
2018
5
Frontal fibrosing alopecia and cutaneous comorbidities: A potential relationship with rosacea. ( 29447678 )
2018
6
A case report of granulomatous rosacea of the face. ( 29748691 )
2018
7
Social factors and aromatase gene expression during adult male-to-female sex change in captive leopard grouper Mycteroperca rosacea. ( 29357278 )
2018
8
Rosacea-like cutaneous localization of small lymphocytic lymphoma unmasked by high-frequency-ultrasound. ( 29790607 )
2018
9
Increased expression of IL-33 in rosacea skin and UVB-irradiated and LL-37-treated HaCaT cells. ( 29873850 )
2018
10
Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for Treatment of Persistent Facial Erythema Associated With Rosacea: Findings From the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials. ( 29409915 )
2018
11
Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0. ( 29879249 )
2018
12
Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations. ( 29943217 )
2018
13
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial. ( 29320594 )
2018
14
Rosacea and alcohol intake. ( 29126626 )
2018
15
To test or not to test: A study examining the return rates of rosacea patients treated with a pulsed dye laser. ( 29388860 )
2018
16
Dual-Frequency Ultrasound as a New Treatment Modality for Refractory Rosacea: A Retrospective Study. ( 29746429 )
2018
17
Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study. ( 29915642 )
2018
18
Fifteen Minute Test May Save 15% or More on Rosacea Treatment. ( 29879260 )
2018
19
IL-1I+ and MMP-9 Tear Levels of Patients with Active Ocular Rosacea before and after Treatment with Systemic Azithromycin or Doxycycline. ( 29874670 )
2018
20
Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes. ( 29771307 )
2018
21
Prevalence of gastrointestinal comorbidities in rosacea: Comparison of subantimicrobial, modified release doxycycline versus conventional release doxycycline. ( 29332715 )
2018
22
Allergic contact dermatitis from formaldehyde mimicking impetigo and initiating rosacea. ( 29611264 )
2018
23
Demodex and rosacea: Is there a relationship? ( 29283119 )
2018
24
Rosacea-like demodicosis and papulopustular rosacea may be two phenotypes of the same disease, and pityriasis folliculorum may be their precursor. Response to the comment of Tatu. ( 29961950 )
2018
25
Applying the phenotype approach for rosacea to practice and research. ( 29799114 )
2018
26
The Evaluation of Contact Sensitivity with Standard and Cosmetic Patch Test Series in Rosacea Patients. ( 29853742 )
2018
27
A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea. ( 29396702 )
2018
28
A Biologically Based Approach to Acne and Rosacea. ( 29879248 )
2018
29
Mesotherapy with Botulinum toxin for the treatment of refractory vascular and papulopustular rosacea. ( 29787842 )
2018
30
Inate immunity in rosacea. Langerhans cells, plasmacytoid dentritic cells, Toll-like receptors and inducible oxide nitric synthase (iNOS) expression in skin specimens: case-control study. ( 29330632 )
2018
31
The impact of age, sex, blepharitis, rosacea and rheumatoid arthritis on <i>Demodex</i> mite infection. ( 29593809 )
2018
32
Daily Oxymetazoline Cream Demonstrates High and Sustained Efficacy in Patients With Persistent Erythema of Rosacea Through 52 Weeks of Treatment. ( 29860043 )
2018
33
Long-term effects of intense pulsed light treatment on the ocular surface in patients with rosacea-associated meibomian gland dysfunction. ( 29958778 )
2018
34
Prescription to Over-the-Counter Switch of Metronidazole and Azelaic Acid for Treatment of Rosacea. ( 29971432 )
2018
35
Reply to: &amp;quot;Rosacea and alcohol intake&amp;quot;. ( 29241804 )
2018
36
Comparison of efficacy between long-pulsed Nd:YAG laser and pulsed dye laser to treat rosacea-associated nasal telangiectasia. ( 29388843 )
2018
37
Long-pulsed 1064-nm Nd: YAG laser ameliorates LL-37-induced rosacea-like skin lesions through promoting collagen remodeling in BALB/c mice. ( 29256058 )
2018
38
Lack of significant anti-inflammatory activity with clindamycin in the treatment of rosacea: results of 2 randomized, vehicle-controlled trials. ( 28873109 )
2017
39
The Role of Skin Care in Optimizing Treatment of Acne and Rosacea. ( 28492949 )
2017
40
Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study. ( 28915286 )
2017
41
Risk of inflammatory bowel disease in patients with rosacea: Results from a nationwide cohort study in Taiwan. ( 28073582 )
2017
42
Granulomatous rosacea: a case report. ( 28822351 )
2017
43
Ocular Rosacea Causing Corneal Melt in an African American Patient and a Hispanic Patient. ( 29158934 )
2017
44
Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component. ( 28889348 )
2017
45
Can Hematologic Parameters be an Indicator of Metabolic Disorders Accompanying Rosacea? ( 28871930 )
2017
46
Immune deficiency and rosacea. ( 28846159 )
2017
47
Low-cost and eco-friendly green synthesis of silver nanoparticles using Prunus japonica (Rosaceae) leaf extract and their antibacterial, antioxidant properties. ( 27396523 )
2017
48
The dermatology life quality index (DLQI) and the hospital anxiety and depression (HADS) in Chinese rosacea patients. ( 28797174 )
2017
49
Rosacea and Helicobacter pylori: links and risks. ( 28848358 )
2017
50
Diet and rosacea: the role of dietary change in the management of rosacea. ( 29214107 )
2017

Variations for Rosacea

Expression for Rosacea

Search GEO for disease gene expression data for Rosacea.

Pathways for Rosacea

Pathways related to Rosacea according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.28 IL6 MMP9 TLR2 TNF VEGFA
2
Show member pathways
12.13 IL6 MMP9 TLR2 TNF
3
Show member pathways
12.1 IL6 TLR2 TNF
4
Show member pathways
12.09 IL6 TLR2 TNF
5 12.08 MMP9 TLR2 TNF VEGFA
6
Show member pathways
12.06 IL6 TLR2 TNF
7
Show member pathways
12.02 IL6 TLR2 TNF
8 12.01 IL6 TNF VEGFA
9 11.92 MMP9 TNF VEGFA
10 11.85 IL6 MMP9 TNF
11 11.79 IL6 MMP9 TNF
12 11.74 IL6 TNF VEGFA
13
Show member pathways
11.73 MMP8 MMP9 TNF
14 11.71 IL6 TLR2 TNF
15 11.68 IL6 MMP9 TNF VEGFA
16 11.61 CAMP IL6 TLR2 TNF VDR
17 11.51 IL6 MMP9 TNF
18 11.51 IL6 TLR2 TNF VEGFA
19 11.46 MMP9 PTGDR VEGFA
20 11.43 IL6 TLR2 TNF
21 11.32 IL6 TLR2 TNF
22 11.29 IL6 MMP9 TNF
23
Show member pathways
11.26 IL6 MMP9 TNF VEGFA
24 11.24 IL6 MMP9 TLR2 TNF VEGFA
25 11.23 IL6 TNF VDR
26 11.15 IL6 TNF
27 11.13 IL6 TNF
28 11.03 MMP9 TLR2
29 11.01 MMP9 VEGFA
30 10.95 IL6 TNF
31 10.88 IL6 TNF
32 10.73 TNF VDR

GO Terms for Rosacea

Cellular components related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 CAMP IL6 MMP8 MMP9 TNF VEGFA
2 intrinsic component of plasma membrane GO:0031226 9.16 TLR2 TRPV1
3 tertiary granule lumen GO:1904724 8.8 CAMP MMP8 MMP9

Biological processes related to Rosacea according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 IL6 TLR2 TNF VDR VEGFA
2 neutrophil degranulation GO:0043312 9.85 CAMP MMP8 MMP9 TLR2
3 positive regulation of apoptotic process GO:0043065 9.78 IL6 MMP9 TNF TRPV1
4 cytokine-mediated signaling pathway GO:0019221 9.76 IL6 MMP9 TNF VEGFA
5 positive regulation of protein phosphorylation GO:0001934 9.73 MMP9 TNF VEGFA
6 inflammatory response GO:0006954 9.72 IL6 PTGDR TLR2 TNF TRPV1
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.71 IL6 TLR2 TNF
8 positive regulation of gene expression GO:0010628 9.65 IL6 TLR2 TNF VDR VEGFA
9 endodermal cell differentiation GO:0035987 9.59 MMP8 MMP9
10 positive regulation of interleukin-8 production GO:0032757 9.58 TLR2 TNF
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.58 IL6 TNF VEGFA
12 positive regulation of protein complex assembly GO:0031334 9.57 TNF VEGFA
13 positive regulation of interleukin-6 production GO:0032755 9.54 IL6 TLR2 TNF
14 macrophage differentiation GO:0030225 9.52 MMP9 VEGFA
15 negative regulation of growth of symbiont in host GO:0044130 9.51 CAMP TNF
16 microglial cell activation GO:0001774 9.49 TLR2 TRPV1
17 cellular response to lipopolysaccharide GO:0071222 9.46 CAMP IL6 TNF VDR
18 negative regulation of lipid storage GO:0010888 9.43 IL6 TNF
19 defense response to Gram-positive bacterium GO:0050830 9.26 CAMP IL6 TLR2 TNF
20 positive regulation of chemokine production GO:0032722 8.8 IL6 TLR2 TNF

Sources for Rosacea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....